Journal
CURRENT DRUG TARGETS
Volume 11, Issue 8, Pages 943-949Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138945010791591313
Keywords
Angiogenesis; microRNA; endothelial cells; atherosclerosis
Categories
Funding
- European Research Council (ERC) [232932]
- Netherlands Scientific Organization (NWO)
- excellence cluster cardiopulmonary system (ECCPS)
- European Research Council (ERC) [232932] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
MicroRNAs are endogenously expressed small non-coding RNAs that regulate gene expression on the posttranscriptional level. During the last years microRNAs have emerged as key regulators of several physiological and pathophysiological processes in the vascular wall. Endothelial cell functions and angiogenesis are critically regulated by microRNAs such as miR-126 and the miR-17-92 cluster in vitro and in vivo. Tumor angiogenesis is additionally controlled by miR-296 and miR-378. MicroRNAs also regulate smooth muscle cell phenotypes and control neointima formation and atherosclerosis. In this respect, miR-143 and miR-145 have been shown to play a crucial role. In this review, we summarize the role of microRNAs and their target genes in endothelial and smooth muscle cells and discuss their applicability as drug targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available